Showing 7601-7610 of 8649 results for "".
- Ocuphire Initiates Enrollment in VEGA-1 Phase 2 Trial Investigating Nyxol in Presbyopiahttps://modernod.com/news/ocuphire-initiates-enrollment-in-vega-1-phase-2-trial-investigating-nyxol-in-presbyopia/2478887/Ocuphire Pharma announced that it has enrolled the first patients in a phase 2 proof of concept trial, titled VEGA-1, to evaluate a combination kit of Nyxol and low-dose pilocarpine in presbyopia. Over 12 sites representing a majority of the planned clinical sites are activated and recruiting pat
- LION Eye Group Collaborates with OCLI-Spectrum Vision Partnershttps://modernod.com/news/lion-eye-group-collaborates-with-ocli-spectrum-vision-partners/2478878/New York-based LION Eye Group announces it has entered into a collaborative agreement with OCLI-Spectrum Vision Partners (OCLI) for integrated eye care. Terms of the deal were not disclosed. “The collaboration was the result of LION’s effort to engage in high quality med
- J&J Submits Single-Dose COVID-19 Vaccine for EMA Reviewhttps://modernod.com/news/jj-submits-single-dose-covid-19-vaccine-for-ema-review/2478881/The European Medicines Agency announced Tuesday that it has received a conditional marketing application for Johnson & Johnson’s COVID-19 vaccine candidate Ad26.COV2.S, and that it intends to review the submission under an accelerated timetable. The regulator indicated that the fi
- Genentech: New Phase 3 Data Show Faricimab the First Investigational Injectable Eye Medicine to Extend Time Between Treatment to Up to 4 Monthshttps://modernod.com/news/new-phase-3-data-show-genentechs-faricimab-is-the-first-investigational-injectable-eye-medicine-to-extend-time-between-treatment-to-up-to-4-months/2478862/Genentech announced detailed results from four phase 3 studies of its investigational bispecific antibody, faricimab, for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). The studies consistently showed that faricimab, given at intervals of up
- Trefoil Therapeutics Begins Second Phase 2 “STORM” Clinical Trial with Regenerative Treatment for Fuchs Endothelial Corneal Dystrophyhttps://modernod.com/news/trefoil-therapeutics-begins-second-phase-2-storm-clinical-trial-with-regenerative-treatment-for-fuchs-endothelial-corneal-dystrophy/2478856/Trefoil Therapeutics announced it has begun a phase 2 clinical trial of its engineered Fibroblast Growth Factor-1, TTHX1114, to evaluate its safety and efficacy as a regenerative treatment for patients with Fuchs Endothelial Corneal Dystrophy (FECD). The “STORM” study, the second clinical trial o
- Focus Vitamins Unveils New Blue Light Product to Help Protect Eyes from Digital Devices and Eye Fatiguehttps://modernod.com/news/focus-vitamins-unveils-new-blue-light-product-to-help-protect-eyes-from-digital-devices-and-eye-fatigue/2478855/Covalent Medical, owner of the brand “Focus Vitamins,” announced today that their new Blue Light mango-flavored gummy will be available to their partner physician practices for resale. “The B.L.U.E. study shows using electronic digital devices can cause eye fatigue, and even interrupt slee
- Johnson & Johnson Vision Celebrates 20 Years of See More Campaign and Global Patient Story Searchhttps://modernod.com/news/johnson-johnson-vision-celebrates-20-years-of-see-more-campaign-and-global-patient-story-search/2478846/Johnson & Johnson Vision announced a month-long celebration of the 20th Anniversary of the Tecnis platform, the proprietary combination of materials and design on which Johnson & Johnson Vision IOLs are built. Twenty years ago, a team of researchers and innovators created Tecnis, setting
- Lumibird Medical Creates Three Nordics Subsidiarieshttps://modernod.com/news/lumibird-medical-creates-three-nordics-subsidiaries/2478848/The Lumibird Medical Group announced the creation of Lumibird Medical Nordics AB in Sweden, Lumibird Medical Nordics OY in Finland, and Lumibird Medical Nordics AS in Norway. The creation of these three subsidi
- JCRS Publishes Phase 2 Nepafenac Clinical Trial With Evolute Sustained Drug Delivery Systemhttps://modernod.com/news/jcrs-publishes-phase-2-nepafenac-clinical-trial-with-evolute-sustained-drug-delivery-system/2478843/Mati Therapeutics announced that a peer reviewed manuscript of a phase 2 clinical trial evaluating the safety and efficacy of Nepafenac delivered via Mati’s proprietary Evolute sustained ocular drug delivery platform has been published in the February Journal of Cataract and Refractive Surgery
- Enteral Lipid Supplement Reduces Severe Retinopathy Risk in Preterm Infantshttps://modernod.com/news/enteral-lipid-supplement-reduces-severe-retinopathy-risk-in-preterm-infants/2478838/Extremely premature infants who receive enteral lipid supplementation starting within 3 days of birth have a lower risk of severe retinopathy of prematurity than without supplementation, a clinical trial suggests, according to a Reuters report